The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

or on the link below. Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...

Please provide your email address to receive an email when new articles are posted on . More than 7% of patients receiving immune checkpoint blockade therapy and antibiotics developed immune-related ...